The influence of remimazolam on the reversal of rocuronium-induced neuromuscular blockade with sugammadex

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1071230073

Enrollment

Registered

2023-10-12

Start date

2023-10-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients scheduled for elective surgery under general anesthesia

Interventions

assignment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients over 18 years old scheduled for elective surgery under general anesthesia. All patients were American Society of Anesthesiologists physical status class I or II.

Exclusion criteria

Exclusion criteria: Patients under 18 years old, emergency surgery, obesity (BMI 30 kg/m2 and more), with hepatic and renal dysfunction, with neuromuscular disorder, with contraindication to benzodiazepine

Design outcomes

Primary

Measure	Time frame
Time from sugamadex administration to TOF ratio 0.90 and more	—

Secondary

Measure	Time frame
Time from initial rocuronium administration to TOF count 0, to reappearance of T1 and T2, and total rocuronium dose used during the surgery.	—

Contacts

Public ContactMasafumi Fujimoto

Kumamoto University Hospital

mfujimoto.kmm@gmail.com+81-96-373-5275

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026